Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Bayer

In this podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented at the ILCA and ESMO congresses, 2022. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.

 

 

 

Dr Matthias Pinter works at the Medical University of Vienna in Austria where he also received both his MD and PhD. He is board-certified for Internal Medicine and Gastroenterology and Hepatology. Since 2017, he has led the hepatocellular carcinoma programme and research group at the Division of Gastroenterology and Hepatology at the Medical University of Vienna. His main research interests include the systemic treatment of liver cancer, particularly the identification of prognostic markers and scores that may help to identify patients most likely to benefit from specific therapies. To broaden his knowledge and expertise in basic research and experimental oncology, he worked as a research fellow and postdoc at renowned institutions, including the University of Bern in Switzerland and the Massachusetts General Hospital/Harvard Medical School in the United States. He has published numerous original papers and review articles on liver cancer in prestigious peer-reviewed journals covering the categories oncology, gastroenterology and hepatology, and radiology.

Assoc. Prof. Matthias Pinter has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, BMS, Ipsen, Eisai, Lilly, MSD and Roche.

Prof. Dr Jeroen Dekervel is a GI oncologist working at the Digestive Oncology Unit of UZ Leuven, Belgium. In daily clinical practice, he treats all kinds of gastrointestinal malignancies at one of the largest clinics of its kind in Europe. He is an associate professor at the KU Leuven, where his research focuses on unraveling the reasons for success and failure of immunotherapies in hepatocellular carcinoma, using a variety of single cell techniques. He is a member of ESMO and ASCO, as well as part of the ESMO upper GI faculty as a mentee.

Prof. Dr Jeroen Dekervel has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Amgen, BMS, Eisai, Ipsen, Lilly, Merck, MSD, Roche, Novartis and Servier. 

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
ER+ metastatic breast cancer: Highlights from the 13th APBCS Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer  

Experts
Prof. Shaheenah Dawood, Prof. Heather McArthur, Prof. Javier Cortés, Prof. Frédérique Penault-Llorca
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Σειρά podcast για τη διαχείριση της θρόμβωσης

Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial

How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?

Experts
Prof. François-Clément Bidard, Dr Barbara Pistilli
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Podcast
Oncology Obstetrics and Gynecology 
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Understanding the role of molecular subtypes in guiding treatment selection

Experts
Prof. Xavier Matias-Guiu, Dr Jurjees Hasan
Endorsed by
Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 11 MIN
  • calendar Feb 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this Video Podcast.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Postępowanie w przypadku zakrzepicy – seria podcastów

Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
Highlights from ASCO GI 2025

Expert insights on BRAF-mutated colorectal cancer

Experts
Dr Elena Élez
Endorsed by
DiCE BRAF Bombers ICAN international cancer advocacy network
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This content is intended for HCPs outside the UK and ROl only.